Wu Ka, Guo Chao, Su Min, Wu Xinmou, Li Rong
Department of Pharmacy, The Second People's Hospital of Nanning City, The Third Affiliated Hospital of Guangxi Medical University Nanning, Nanning, China.
Department of Pharmacy, Guigang City People's Hospital, The Eighth Affiliated Hospital of Guangxi Medical University, Guigang, China.
Cell Physiol Biochem. 2017;43(4):1562-1570. doi: 10.1159/000482003. Epub 2017 Oct 16.
BACKGROUND/AIMS: Acetaminophen (APAP) refers to a medication used to manage pain and fever symptoms. Heat shock protein 90 (Hsp90) is to be expressed during various stresses, such as wound healing and tissue remodeling. Recently, it is discovered that Hsp90 is a potential modifier of cytogenesis. In comparison to clinical references of liver damage, this study was designed to assess the potential bioeffect of Hsp90 in APAP-treated livers without conspicuous drug induced liver injury (DILI).
In our current study, human plasma samples of APAP-used patients were collected for biochemical assays in clinical parameters. Adult male mice were used to investigate the biocharacterization of Hsp90 in APAP-treated livers through serological tests and immunoassays. Further, a mouse liver cell strain was employed in assessment of bioeffect of APAP on hepatocellular Hsp90 expression.
Correspondingly, the clinical data showed APAP-administered patients resulted in increased Hsp90 levels in serum when compared to other clinical parameters of liver injury. In adult mice study, APAP-treated livers showed unchanged hepatocellular and metabolic functions, as highlighted in biochemical analysis and immunoassay. Notably, Hsp90 expression in APAP-treated mice were elevated in the serum and liver samples. In quantitative western blot assay, the present data suggested that hepatocellular Hsp90 level was up-regulated followed by APAP treatment. In mouse cell strain study, APAP-treated liver cells had increased trend of aminotransferase contents and apoptotic counts. Further, endogenous Hsp90 expression in APAP-exposed cells was increased dose- and time-dependently.
In conclusion, our current findings disclose that Hsp90 biomolecule may be a potential indicator for APAP-induced inconspicuous DILI, in which it seems to be characterized with more sensitive than other diagnosis criteria.
背景/目的:对乙酰氨基酚(APAP)是一种用于控制疼痛和发热症状的药物。热休克蛋白90(Hsp90)在各种应激过程中表达,如伤口愈合和组织重塑。最近发现,Hsp90是细胞发生的潜在调节因子。与肝损伤的临床参考指标相比,本研究旨在评估Hsp90在未出现明显药物性肝损伤(DILI)的APAP处理肝脏中的潜在生物效应。
在我们目前的研究中,收集使用APAP患者的人血浆样本进行临床参数的生化检测。使用成年雄性小鼠通过血清学检测和免疫测定来研究Hsp90在APAP处理肝脏中的生物特性。此外,使用小鼠肝细胞系评估APAP对肝细胞Hsp90表达的生物效应。
相应地,临床数据显示,与肝损伤的其他临床参数相比,服用APAP的患者血清中Hsp90水平升高。在成年小鼠研究中,APAP处理的肝脏在生化分析和免疫测定中显示肝细胞和代谢功能未改变。值得注意的是,APAP处理小鼠的血清和肝脏样本中Hsp90表达升高。在定量蛋白质免疫印迹分析中,目前的数据表明,APAP处理后肝细胞Hsp90水平上调。在小鼠细胞系研究中,APAP处理的肝细胞转氨酶含量和凋亡计数有增加趋势。此外,APAP处理细胞中内源性Hsp90表达呈剂量和时间依赖性增加。
总之,我们目前的研究结果表明,Hsp90生物分子可能是APAP诱导的不明显DILI的潜在指标,其特征似乎比其他诊断标准更敏感。